Irsogladine
Irsogladine is a PDE4 inhibitor and muscarinic acetylcholine receptor binder. Target: PDE4; mACHR Irsogladine treatment (300 and 500 mg/kg/day) resulted in a dose-dependent reduction of angiogenesis in wild-type mice by 21 and 45.3% (P < 0.02, P < 0.001), in tPA-deficient mice by 42.6 and 46% (P < 0.001, P < 0.001), and in uPA-deficient mice by 27.2 and 46% (P < 0.05, p < 0.001), respectively. Irsogladine inhibits bFGF-induced angiogenesis in wild-type, tPA-knockout, and uPA-knockout mice [1]. Irsogladine up-regulates GJIC between PC cells via regulation of the PKA pathway. It also suggests a useful adjuvant of Irsogladine to pancreatic cancer therapy [2]. irsogladine produces the increase of intracellular cAMP content via non-selective inhibition of PDE isozymes, which may be a key mechanism involved in its gastroprotective actions [3].
Product Specifications
CAS Number
[57381-26-7]
Product Name Alternative
Dicloguamine
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
MAChR; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Irsogladine.html
Concentration
10mM
Purity
99.88
Solubility
DMSO : 120 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)
Smiles
NC1=NC(N)=NC(C2=CC(Cl)=CC=C2Cl)=N1
Molecular Formula
C9H7Cl2N5
Molecular Weight
256.09
Precautions
H302, H312, H332
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDE4
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items